Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A group of state attorneys general unveiled on Wednesday a landmark, $26 billion settlement resolving claims that the three largest US drug distributors and drugmaker Johnson & Johnson helped fuel a deadly nationwide opioid epidemic. Under the settlement proposal, distributors McKesson, Cardinal Health and AmerisourceBergen are expected to pay a combined $21 billion, while Johnson.

Big 3 drug distributors, J&J reach landmark $26B opioid settlement

Coca-Cola

Block

Chipotle

Square, Johnson & Johnson, Coca-Cola and Chipotle Mexican Grill were our top stock trades for Thursday. Now, let's look at the charts.

4 Top Stock Trades for Thursday: SQ, JNJ, KO, CMG

AmerisourceBergen

Cardinal Health

McKesson

States unveiled a historic $26 billion settlement with drug companies to resolve thousands of opioid-crisis lawsuits, paving the way for communities across the country to secure a jolt of funding to address an epidemic in painkiller addiction that hasn't abated.

The Wall Street Journal: States announce $26 billion settlement to resolve opioid lawsuits

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

A modest day of gains after the three stalwarts reported results that met investor expectations.

Dow Jones Up 270 Points After Coca-Cola, Johnson & Johnson, Verizon Announce Earnings

A group of states Attorneys General announced a proposed $26 billion global settlement Wednesday that, if approved, will resolve claims against the "big three" drug distributors — McKesson Corporation, Cardinal Health Inc. and Amerisource Bergen Drug Corporation — and opioid manufacturer Johnson & Johnson.

Attorneys General propose a $26 billion global opioid settlement with the 'big three' drug distributors

The deal will resolve thousands of opioid crisis-related lawsuits.

J&J And Other Drug Companies Strike $26 Billion Opioid Settlement With States

Shares of Johnson & Johnson were up 0.3% in trading on Wednesday after a dozen or so state attorneys general announced an opioid settlement that requires J&J to pay $5 billion over nine years, including $3.7 billion in payments over the first three years. The company is also required to stop selling opioids for 10 years, and it cannot fund or provide grants to organizations that promote opioids or lobby on opioids during that time period.

J&J to stop selling opioids for 10 years and will pay $5 billion as part of settlement

As the Delta variant rapidly spreads across the U.S., accounting for 83% of the country's cases, a new study showed that neutralizing titers induced by Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine decreased 5.4-fold against the Delta plus variant. What Happened: In comparison, titers induced by Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) candidate decreased by 2.7-fold against the Delta plus variant, and levels dropped 3.3-fold for Moderna Inc's (NASDAQ: MRNA) candidate.

Johnson & Johnson's COVID-19 Shot Is Less Effective Against Delta Variant: Study

Today in healthcare, Johnson & Johnson pointed to medical device sales as one of the keys to its Q2 growth, and doctors with better digital tools are becoming increasingly attractive to patients. Plus, telemedicine's bubble could burst without better data security.

Today In Healthcare: Medical Devices Boost J&J Q2, Patients Prefer Docs With Better Digital Tools And Data Breaches Threaten Telehealth

Johnson & Johnson (JNJ) on Q2 2021 Results - Earnings Call Transcript

Shares of Johnson & Johnson ( JNJ , Financial), one of Yacktman Asset Management (Trades, Portfolio)'s top 10 holdings, rose slightly above the flatline on Wednesday after reporting second-quarter earnings that topped consensus estimates.

Yacktman Holding Johnson & Johnson Rises on 2nd-Quarter Earnings Beat

Johnson & Johnson posted strong second-quarter results on Tuesday (July 21), beating Wall Street estimates as sales of beauty and skincare products begin to recover from COVID-19 and patients resume previously deferred medical procedures. The New Jersey-based company reported over $23 billion in sales for the three months ending June 30, a 27 percent year-over-year […]

Johnson & Johnson Q2 Growth Driven By Consumer Products, Medical Devices

J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises

Johnson & Johnson said it will sell $2.5 billion worth of its COVID-19 vaccine this year and pushed back against concerns over its effectiveness against the delta variant.

Johnson & Johnson forecasts $2.5B of coronavirus vaccine sales

Part of the blue-chip earnings deluge this morning, the shares of Johnson & Johnson  (NYSE:JNJ) are down 0.5% at $167.76 at last check, despite the pharma giant reporting better-than-expected second-quarter earnings, as well as a revenue beat.

Johnson & Johnson Stock Unable to Score Post-Earnings Pop

Johnson & Johnson revealed that it expects to take home about $2.5 billion from COVID-19 vaccine sales in 2021, far lower than estimates from its jab rivals Moderna and Pfizer.

J&J forecasts $2.5B COVID vaccine sales this year, lagging rivals

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 8.77% and 4.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates

Johnson & Johnson (NYSE: JNJ) reported Q2 adjusted earnings of $2.48 per share, almost 50% higher than the $1.67 posted a year ago and better than the consensus of $2.27. Net sales increased 27% Y/Y to $23.3 billion, and ahead of the $22.1 billion consensus.

Johnson & Johnson Q2 Earnings Beat Expectations; Raises FY21 Outlook, Sees $2.5B Sales From COVID Vaccine

Global sales of the Covid vaccine in the quarter were $164 million.

Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year

Johnson & Johnson shares rose 1.1% in premarket trade Wednesday, after the consumer and health company beat earnings estimates for the second quarter and raised its full-year guidance. The company said it had net income of $6.278 billion, or $2.35 a share, up from $3.626 billion, or $1.36 a share, in the year-earlier period.

Johnson & Johnson beats earnings estimates for Q2 and raises full-year guidance

Johnson & Johnson raised its 2021 revenue estimates on Wednesday and forecast it would sell $2.5 billion worth of its COVID-19 vaccine this year, as it strives to quell production and safety problems and catch up with rivals Pfizer and Moderna.

J&J raises revenue forecast, estimates $2.5 billion in COVID-19 vaccine sales

The global tally for the coronavirus-borne illness climbed above 191.4 million on Wednesday, while the death toll climbed above 4.1 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 34 million cases and in deaths with 609,529 as the highly infectious delta variant continues to spread fast, especially in states with low vaccination rates.

Coronavirus tally: Global cases of COVID-19 top 191.4 million and study finds J&J vaccine less effective vs. delta variant

NEW BRUNSWICK, N.J., July 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter.

Johnson & Johnson Reports Q2 2021 Results

The study, which examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggests that anyone who received the J&J vaccine may need to receive a second shot as the variant continues to spread across the US.

The New York Post: Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study

More than 13 million Americans have received the J&J vaccine.

News for Johnson & Johnson Stock (JNJ)